The present invention provides a recombinant Vaccinia virus as a dengue virus vaccine that can be used as a therapeutic or prophylactic agent in the clinic. This recombinant Vaccinia virus is characterized by including: all or part of a cDNA that encodes a non-structural protein from a dengue virus; and an expression promoter.

A method to enhance an immune response in a mammal, and a composition comprising liposomes, a TLR4 agonist and a TLR7 agonist, are provided.

The present invention is directed to a live-attenuated Mycobacterium tuberculosis composition comprising an isolated microorganism belonging to a M. tuberculosis MTB VAC strain having a i) PhoP− phenotype by the inactivation by a genetic deletion of the Rv0757 gene, wherein the open-reading frame (ORF) sequence of phoP consists of SEQ ID NO 4, and ii) the deletion of a second gene, Rv2930 (fadD26), that prevents PDIM production (PDIM− phenotype), wherein the open-reading frame (ORF) sequence of fadD26 consists of SEQ ID NO 2, for use in therapy in a human subject in need thereof, wherein the composition is administered to said subject via pulmonary delivery.

Disclosed are animal feed compositions comprising a saponin extracted from a non-woody plant of the genus Hesperaloe. The saponin containing extracts, which generally constitute the water soluble fraction, are useful as additives to basal animal feed to reduce the production of ammonia. In certain embodiments, saponin containing compositions of the present invention may inhibit proteolytic microorganisms, reducing ammonia and improving animal welfare and animal performance. In other embodiments, administration of saponin containing compositions of the present invention to non-human animal inhibits the release of gaseous ammonia through the inhibition urease. The compositions of the present invention may be administered to non-human animals, particularly poultry, to reduce ammonia emissions. In certain embodiment, the animal feed composition comprises a basal animal feed and an extract from a non-woody plant of the genus Hesperaloe, the extract comprising 25(27)-dehydrofucreastatin, 5(6), 25(27)-disdehydroyuccaloiside C, 5(6)-disdehydroyuccaloiside C, furcreastatin, yuccaloiside, or a mixture thereof.

Administering a live, attenuated Bordetella pertussis-based vaccine to a subject at risk for developing a neurodegenerative disease featuring Aβ brain plaques can prevent or reduce the amount of Aβ brain plaques that would have developed in the subject without such treatment.

The invention relates to multiple epitope constructs, immunogenic and vaccine compositions comprising recombinant molecules presenting inserted multiple and different epitopes from a variety of antigens. The antigenic determinants being associated with different pathways leading to atherosclerosis. In particular, the invention relates to such compositions for eliciting an immune response against antigens and pathogens involved in the development of atherosclerosis the invention includes inter alia methods of treating and/or preventing the disease and recombinant protein products.

The present invention relates to a method for preparing cDNA infectious clones based on the genome of an attenuated Porcine Reproductive and Respiratory Syndrome virus (PRRSV) and uses thereof for preparing efficacious and safety-enhanced vaccines against PRRSV. The invention further comprises an infectious cDNA clone obtainable by such method. The invention further provides an attenuated modified PRRSV, and immunogenic compositions and vaccines comprising that attenuated PRRSV. The present invention further provides the attenuated PRRSV for use in the prophylaxis and/or the treatment of PRRSV infections, and the attenuated PRRSV for use as vaccine or medicament in the prophylaxis and/or the treatment of PRRSV infections.

The present invention relates to an immunogenic fusion protein comprising a first amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of a first group B Streptococcus surface protein, which is fused to a second amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of a second group B Streptococcus surface protein. Each of the first and the second group B Streptococcus surface protein is selected from the group consisting of Rib protein, Alp1 protein, Alp2 protein, Alp3 protein, Alp4 protein and AlpC protein. The immunogenic fusion protein further comprises at least one amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of the group B streptococcus surface protein Alp1, Alp2, Alp3 or Alp4. The invention further pertains to an isolated nucleotide sequence encoding the immunogenic fusion protein; a vector; a host cell; an immunogenic product, a vaccine; and a method for preventing or treating a group B Streptococcus infection.

Described herein are compositions and methods for inducing Type I interferon production. The compositions described comprise immunostimulatory oligonucleotide duplexes including a 5′ terminal monophosphate-CUGA-3′ (SEQ ID NO. 1) sequence. Compositions comprising the immunostimulatory oligonucleotide duplexes described can be used for the treatment of diseases or disorders that respond to interferons.

In certain embodiments, the disclosure relates to the polynucleotide sequences of respiratory syncytial virus (RSV). In certain embodiments, the disclosure relates to isolated or recombinant nucleic acids and polypeptides comprising desirable nucleic acid sequences and mutations disclosed herein. In certain embodiments, isolated or recombinant RSV comprising the nucleic acids and polypeptides disclosed herein (e.g., attenuated recombinant RSV) are also provided, as are immunogenic compositions including such nucleic acids, polypeptides, and RSV genomes that are suitable for use as vaccines. Attenuated or killed RSV containing these nucleic acids and mutation in the form of copied nucleic acids (e.g., cDNAs) are also contemplated.